Avalo Therapeutics AVTX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $55.01M+9.8% | $50.09M+11.3% | $45M+10.0% | $40.92M+30.1% | $31.45M+28.7% | ||
| $24.21M+5.7% | $22.9M+6.0% | $21.6M+6.4% | $20.31M+3.6% | $19.59M+13.6% | ||
| $79.22M+8.5% | $72.98M+9.4% | $66.69M+10.0% | $60.6M+19.2% | $50.86M-26.2% | ||
| -$79.16M-8.5% | -$72.93M-9.7% | -$66.49M-10.5% | -$60.16M-19.3% | -$50.42M+26.4% | ||
| $4.01M-7.9% | $4.35M-5.0% | $4.58M+3.5% | $4.43M+1.4% | $4.36M+31.6% | ||
| —— | —— | —— | —— | —— | ||
| -$84.57M-8.3% | -$78.09M+21.7% | -$99.73M-116% | -$46.09M-163% | $73.13M+309% | ||
| $169K+2.4% | $165K+10.7% | $149K+20.2% | $124K+7.8% | $115K+0.9% | ||
| -$84.74M-8.3% | -$78.26M+21.6% | -$99.88M-116% | -$46.22M-163% | $73.01M+308% | ||
| -$5.46+4.7% | -$5.73— | —— | —— | —— | ||
| -$78.93M-8.7% | -$72.58M-9.8% | -$66.1M-10.6% | -$59.79M-19.2% | -$50.15M+26.6% | ||
| -$79.16M-8.5% | -$72.93M-9.7% | -$66.49M-10.5% | -$60.16M-19.3% | -$50.42M+26.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Avalo Therapeutics's revenue?
- Avalo Therapeutics (AVTX) generated $500.0K in revenue over the trailing twelve months, down 38.0% year over year.
- Is Avalo Therapeutics profitable?
- Avalo Therapeutics is not currently profitable: it reported a net loss of $84.7M over the trailing twelve months, a -7965.8% net margin.
- What are Avalo Therapeutics's profit margins?
- Gross margin is 182.0% and operating margin is -15536.1%, with a -7965.8% net margin.
- What is Avalo Therapeutics's earnings per share?
- Avalo Therapeutics's diluted EPS over the trailing twelve months is $-5.46.
- Where does Avalo Therapeutics's income statement data come from?
- Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
